Australian researchers have discovered that a compound derived from sea squirts can significantly inhibit the growth of melanoma tumors in mice, opening a potential new avenue for treating the deadly skin cancer. The study, published in the journal Nature Communications, found that the compound, known as aplidine, targets a specific protein that melanoma cells rely on to survive and proliferate.
How the Compound Works
Aplidine, originally isolated from the sea squirt Aplidium albicans, works by blocking the activity of a protein called eEF1A2, which is overexpressed in melanoma cells. According to lead researcher Dr. Maria Kavallaris from the Children's Cancer Institute in Sydney, this protein is critical for the cancer cells' ability to produce new proteins and grow. “By inhibiting eEF1A2, we essentially starve the melanoma cells of the tools they need to multiply,” she said.
The compound was tested on mice with human melanoma tumors. After 21 days of treatment, tumor growth was reduced by up to 80% compared to the control group. Importantly, the treatment showed minimal side effects, with no significant weight loss or organ toxicity observed in the mice.
Implications for Human Treatment
While the results are promising, researchers caution that further studies are needed before aplidine can be tested in humans. “This is a very early-stage discovery, but it provides a strong foundation for developing a new class of melanoma drugs,” said Dr. Kavallaris. “Melanoma is notoriously difficult to treat once it has spread, so finding new targets is crucial.”
Melanoma is the third most common cancer in Australia, with over 15,000 new cases diagnosed each year. Current treatments include surgery, immunotherapy, and targeted therapies, but resistance to these treatments often develops. The sea squirt compound offers a different mechanism of action, which could be used alone or in combination with existing therapies.
Next Steps in Research
The research team is now working to optimize the compound for human use and to understand how it might be combined with other melanoma treatments. They are also investigating whether aplidine could be effective against other cancers that rely on eEF1A2, such as pancreatic and lung cancers.
The study was funded by the National Health and Medical Research Council and the Cancer Institute NSW. The researchers have filed a patent for the use of aplidine in cancer treatment.
